ReviewFrontiers in molecular medicine2026

CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy.

Masuko Katoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.